- Home
- ACRE vs OLMA Comparison
ACRE vs OLMA Comparison
Compare ACRE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- OLMA
- Stock Information
- Founded
- ACRE 2011
- OLMA 2006
- Country
- ACRE United States
- OLMA United States
- Employees
- ACRE N/A
- OLMA N/A
- Industry
- ACRE Real Estate Investment Trusts
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- OLMA Health Care
- Exchange
- ACRE Nasdaq
- OLMA Nasdaq
- Market Cap
- ACRE 259.5M
- OLMA 289.0M
- IPO Year
- ACRE 2012
- OLMA 2020
- Fundamental
- Price
- ACRE $3.60
- OLMA $4.42
- Analyst Decision
- ACRE Hold
- OLMA Strong Buy
- Analyst Count
- ACRE 7
- OLMA 3
- Target Price
- ACRE $5.19
- OLMA $27.67
- AVG Volume (30 Days)
- ACRE 782.4K
- OLMA 1.2M
- Earning Date
- ACRE 05-08-2025
- OLMA 05-07-2025
- Dividend Yield
- ACRE 25.00%
- OLMA N/A
- EPS Growth
- ACRE N/A
- OLMA N/A
- EPS
- ACRE N/A
- OLMA N/A
- Revenue
- ACRE $87,802,000.00
- OLMA N/A
- Revenue This Year
- ACRE N/A
- OLMA N/A
- Revenue Next Year
- ACRE $11.57
- OLMA N/A
- P/E Ratio
- ACRE N/A
- OLMA N/A
- Revenue Growth
- ACRE 7874.75
- OLMA N/A
- 52 Week Low
- ACRE $3.35
- OLMA $2.86
- 52 Week High
- ACRE $7.99
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- ACRE 29.45
- OLMA 60.78
- Support Level
- ACRE $3.45
- OLMA $2.96
- Resistance Level
- ACRE $3.84
- OLMA $3.41
- Average True Range (ATR)
- ACRE 0.25
- OLMA 0.35
- MACD
- ACRE -0.04
- OLMA 0.16
- Stochastic Oscillator
- ACRE 18.12
- OLMA 98.73
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.